Rakovina Therapeutics Inc. announced a summary of the Company?s presentation at the sixth biennial Canadian Cancer Research Conference, being held virtually November 8, 2021 - November 11, 2021. Rakovina Therapeutics presented a poster presentation entitled In Vitro Activity of Novel Dual PARP-HDAC Inhibitors, which described results of the Company?s research related to the development of its novel kt-3000 series novel drug candidates. The Company will make its poster presentation available on its website following the conclusion of the meeting. In summary, the data suggests promising activity for kt-3000 series compounds against both BRCA wild-type and BRCA mutant cancers, benchmarked against an FDA-approved PARP inhibitor. PARP inhibitors target cancer cells with BRCA mutations by taking advantage of their reduced DNA-repair capacity to selectively kill cancer cells. An established mechanism of resistance to PARP inhibitors involves the restoration of BRCA1 or BRCA2 genes to their wild-type state. When a cancer cell is able to restore BRCA function, PARP-inhibitors become less effective.